<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="180095">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00750269</url>
  </required_header>
  <id_info>
    <org_study_id>RTOG-0813</org_study_id>
    <secondary_id>CDR0000613524</secondary_id>
    <secondary_id>NCI-2009-01095</secondary_id>
    <nct_id>NCT00750269</nct_id>
    <nct_alias>NCT01317056</nct_alias>
  </id_info>
  <brief_title>Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer</brief_title>
  <official_title>Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>NRG Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radiation Therapy Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the
      tumor and cause less damage to normal tissue.

      PURPOSE: This phase I/II trial is studying the side effects and best dose of stereotactic
      body radiation therapy and to see how well it works in treating patients with stage I
      non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the maximum tolerated dose (MTD) of stereotactic body radiotherapy (SBRT)
           in medically inoperable patients with centrally located stage I non-small cell lung
           cancer. (Phase I)

        -  To determine the efficacy of SBRT when administered at the MTD in these patients.
           (Phase I)

        -  To estimate the local control rate of SBRT at the MTD in these patients. (Phase II)

      Secondary

        -  To estimate the rates of adverse events (other than dose-limiting toxicity) of ≥ grade
           3 that is possibly, probably, or definitely related to treatment and that occurs within
           1 year after the start of SBRT in these patients.

        -  To estimate the rates of late adverse events (i.e., occurs &gt; 1 year after the start of
           SBRT) in these patients.

        -  To estimate the local control and progression-free and overall survival rates in
           patients treated with this regimen.

      OUTLINE: This is a multicenter study.

      Patients undergo stereotactic body radiotherapy every 2 days over 1½-2 weeks (total of 5
      fractions) in the absence of disease progression or unacceptable toxicity.

      After completion of study therapy, patients are followed periodically.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2009</start_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of stereotactic body radiotherapy (SBRT) as assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v4.0 (Phase I)</measure>
    <time_frame>From start of SBRT until 1 year.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To estimate the primary tumor control rate at the maximum tolerated dose (MTD)</measure>
    <time_frame>From start of SBRT until 2 years.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From randomization to date of death, failure (local, regional or distant) or last follow-up. Analysis occurs after all patients have been potentially followed for 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From randomization to date of death or last follow-up. Analysis occurs after all patients have been potentially followed for 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to local progression</measure>
    <time_frame>From randomization to date of death, regional failure or last follow-up. Analysis occurs after all patients have been potentially followed for 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to regional nodal progression</measure>
    <time_frame>From randomization to date of death, regional failure or last follow-up. Analysis occurs after all patients have been potentially followed for 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to distant metastases</measure>
    <time_frame>From randomization to date of death, distant failure or last follow-up. Analysis occurs after all patients have been potentially followed for 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (other than DLT) of ≥ grade 3 as assessed by NCI CTCAE v4.0</measure>
    <time_frame>From start of SBRT until 1 year.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity (i.e., occurs &gt; 1 year after the start of SBRT) of ≥ grade 3 as assessed by NCI CTCAE v4.0</measure>
    <time_frame>From start of treatment to end of follow-up.</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Level 1: 8 Gy x 5 fractions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>stereotactic body radiation therapy (SBRT) of 8 Gy x 5 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Level 2: 8.5 Gy x 5 fractions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>stereotactic body radiation therapy (SBRT) of 8.5 Gy x 5 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Level 3: 9 Gy x 5 fractions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>stereotactic body radiation therapy (SBRT) of 9 Gy x 5 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Level 4: 9.5 Gy x 5 fractions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>stereotactic body radiation therapy (SBRT) of 9.5 Gy x 5 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Level 5: 10 Gy x 5 fractions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>stereotactic body radiation therapy (SBRT) of 10 Gy x 5 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Level 6: 10.5 Gy x 5 fractions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>stereotactic body radiation therapy (SBRT) of 10.5 Gy x 5 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Level 7: 11 Gy x 5 fractions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>stereotactic body radiation therapy (SBRT) of 11 Gy x 5 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Level 8: 11.5 Gy x 5 fractions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>stereotactic body radiation therapy (SBRT) of 11.5 Gy x 5 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Level 9: 12 Gy x 5 fractions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>stereotactic body radiation therapy (SBRT) of 12 Gy x 5 fractions</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic body radiation therapy (SBRT)</intervention_name>
    <arm_group_label>Level 1: 8 Gy x 5 fractions</arm_group_label>
    <arm_group_label>Level 2: 8.5 Gy x 5 fractions</arm_group_label>
    <arm_group_label>Level 3: 9 Gy x 5 fractions</arm_group_label>
    <arm_group_label>Level 4: 9.5 Gy x 5 fractions</arm_group_label>
    <arm_group_label>Level 5: 10 Gy x 5 fractions</arm_group_label>
    <arm_group_label>Level 6: 10.5 Gy x 5 fractions</arm_group_label>
    <arm_group_label>Level 7: 11 Gy x 5 fractions</arm_group_label>
    <arm_group_label>Level 8: 11.5 Gy x 5 fractions</arm_group_label>
    <arm_group_label>Level 9: 12 Gy x 5 fractions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)

               -  Stage T1-2, N0, M0 disease

                    -  Tumor size ≤ 5 cm

                    -  Tumor must be within or touching the zone of the proximal bronchial tree,
                       defined as a volume of 2 cm in all directions around the proximal bronchial
                       tree (i.e., carina, right and left main bronchi, right and left upper lobe
                       bronchi, intermedius bronchus, right middle lobe bronchus, lingular
                       bronchus right, and left lower lobe bronchi) OR immediately adjacent to the
                       mediastinal or pericardial pleura (PTV touching the pleura)

                    -  Hilar or mediastinal lymph nodes ≤ 1 cm AND no abnormal hilar or
                       mediastinal uptake on PET scan are considered N0

                         -  Mediastinal lymph node sampling by any technique is allowed but not
                            required

                         -  Patients with &gt; 1 cm hilar or mediastinal lymph nodes on CT scan or
                            abnormal PET scan (including suspicious but nondiagnostic uptake) are
                            eligible provided directed tissue biopsies of all abnormally
                            identified areas are negative for cancer

          -  Tumor deemed technically resectable, in the opinion of an experienced thoracic cancer
             surgeon, with a reasonable possibility of obtaining a gross total resection with
             negative margins, defined as a potentially curative resection (PCR)

          -  Patient deemed &quot;medically inoperable&quot; due to severe underlying physiological medical
             problems that would prohibit a PCR, including any of the following:

               -  Baseline forced expiratory volume at one second (FEV1) &lt; 40% predicted

               -  Postoperative FEV1 &lt; 30% predicted

               -  Severely reduced diffusion capacity

               -  Baseline hypoxemia and/or hypercapnia

               -  Exercise oxygen consumption &lt; 50% predicted

               -  Severe pulmonary hypertension

               -  Diabetes mellitus with severe end-stage organ damage

               -  Severe cerebral, cardiac, or peripheral vascular disease

               -  Severe chronic heart disease

          -  Measurable disease as documented by CT scan or whole-body PET scan within the past 8
             weeks

               -  Patients with lesions that cannot be visualized by CT scan are not eligible

          -  Pleural effusion allowed provided it is deemed too small to tap under CT guidance and
             is not evident on chest x-ray

               -  Pleural effusion that appears on chest x-ray is allowed only after thoracotomy
                  or other invasive procedure

        PATIENT CHARACTERISTICS:

          -  Zubrod performance status 0-2

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for ≥ 60 days after
             completion of study therapy

          -  No other invasive malignancy within the past 2 years except nonmelanomatous skin
             cancer or carcinoma in situ of the breast, oral cavity, or cervix

               -  Prior lung cancer allowed provided the patient has been disease-free for ≥ 2
                  years

        PRIOR CONCURRENT THERAPY:

          -  No prior radiotherapy to the region of the study cancer that would result in overlap
             of radiotherapy fields

          -  No prior chemotherapy for the study cancer

          -  No other concurrent local therapy (including standard-fractionated radiotherapy
             and/or surgery) or systemic therapy (including standard chemotherapy or biologic
             targeted agents) specifically intended as treatment for study cancer

               -  Local or systemic therapy at the time of disease progression allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Bezjak, MD, MSC, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Bradley, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mallinckrodt Institute of Radiology at Washington University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurie E. Gaspar, MD, MBA</last_name>
    <role>Study Chair</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Center for Cancer Care - Peoria</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259-5499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiation Oncology Centers - Cameron Park</name>
      <address>
        <city>Cameron Park</city>
        <state>California</state>
        <zip>95682</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Cancer Center at Mercy San Juan Medical Center</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Christiana Care Health Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Cancer Institute - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center at Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSF St. Francis Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Kansas City</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucille P. Markey Cancer Center at University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Suburban Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Cancer Center Office of Clinical Research</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71315-3198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Center for Cancer Medicine and Blood Disorders - Scarborough</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenebaum Cancer Center at University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephine Ford Cancer Center at Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McLaren Cancer Institute</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Butterworth Hospital at Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lacks Cancer Center at Saint Mary's Health Care</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital - Royal Oak Campus</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy and Unity Cancer Center at Mercy Hospital</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy and Unity Cancer Center at Unity Hospital</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Piper Cancer Institute at Abbott - Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regions Hospital Cancer Care Center</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper CyberKnife Center</name>
      <address>
        <city>Mount Laurel</city>
        <state>New Jersey</state>
        <zip>08054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frederick R. and Betty M. Smith Cancer Treatment Center</name>
      <address>
        <city>Sparta</city>
        <state>New Jersey</state>
        <zip>07871</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's - Roosevelt Hospital Center - St.Luke's Division</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center at University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summa Center for Cancer Care at Akron City Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44309-2090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles M. Barrett Cancer Center at University Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flower Hospital Cancer Center</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <zip>43560</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rosenfeld Cancer Center at Abington Memorial Hospital</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dale and Frances Hughes Cancer Center at Pocono Medical Center</name>
      <address>
        <city>East Stroudsburg</city>
        <state>Pennsylvania</state>
        <zip>18301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frankford Hospital Cancer Center - Torresdale Campus</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <zip>19612-6052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lankenau Cancer Center at Lankenau Hospital</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Cancer Institute at Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Cancer Center</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Cancer Center at University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Milwaukee</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 13, 2015</lastchanged_date>
  <firstreceived_date>September 9, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
